Overview

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study. The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University

Collaborators:

Liaoning Tumor Hospital & Institute
Zhejiang University

Treatments:

Bevacizumab
Calcium
Calcium, Dietary
Camptothecin
Capecitabine
Cetuximab
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin